{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:32:05Z","timestamp":1789104725874,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Radiol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00256-024-04855-5","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T07:09:55Z","timestamp":1734678595000},"page":"1479-1489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Performance of PSMA-PET\/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1997-1360","authenticated-orcid":false,"given":"William C.","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin E.","family":"Northrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino M.","family":"Dettorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston L.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resten","family":"Imaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore L.","family":"Vander Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"1","key":"4855_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4855_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13550-020-00618-0","volume":"10","author":"HD Zacho","year":"2020","unstructured":"Zacho HD, Ravn S, Afshar-Oromieh A, Fledelius J, Ejlersen JA, Petersen LJ. Added value of 68Ga-PSMA PET\/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy. EJNMMI Res. 2020;10(1):31.","journal-title":"EJNMMI Res"},{"issue":"3","key":"4855_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2214\/AJR.21.27323","volume":"219","author":"G Zhao","year":"2022","unstructured":"Zhao G, Ji B. Head-to-head comparison of 68Ga-PSMA-11 PET\/CT and 99mTc-MDP bone scintigraphy for the detection of bone metastases in patients with prostate cancer: a meta-analysis. AJR Am J Roentgenol. 2022;219(3):386\u201395.","journal-title":"AJR Am J Roentgenol"},{"issue":"10231","key":"4855_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316.","journal-title":"Lancet"},{"issue":"21","key":"4855_CR5","doi-asserted-by":"publisher","first-page":"5286","DOI":"10.3390\/cancers13215286","volume":"13","author":"J Van Damme","year":"2021","unstructured":"Van Damme J, Tombal B, Collette L, et al. Comparison of 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography computed tomography (PET-CT) and whole-body magnetic resonance imaging (WB-MRI) with diffusion sequences (DWI) in the staging of advanced prostate cancer. Cancers (Basel). 2021;13(21):5286.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"4855_CR6","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00256-019-03230-z","volume":"48","author":"J Zhou","year":"2019","unstructured":"Zhou J, Gou Z, Wu R, Yuan Y, Yu G, Zhao Y. Comparison of PSMA-PET\/CT, choline-PET\/CT, NaF-PET\/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skelet Radiol. 2019;48(12):1915\u201324.","journal-title":"Skelet Radiol"},{"issue":"1","key":"4855_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1148\/radiol.2020191689","volume":"296","author":"N Tan","year":"2020","unstructured":"Tan N, Oyoyo U, Bavadian N, et al. PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology. 2020;296(1):44\u201355.","journal-title":"Radiology"},{"issue":"1","key":"4855_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206(1):52\u201361.","journal-title":"J Urol"},{"issue":"13","key":"4855_CR9","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","volume":"27","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27(13):3674\u201382.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4855_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/pros.22742","volume":"74","author":"G Gandaglia","year":"2014","unstructured":"Gandaglia G, Abdollah F, Schiffmann J, et al. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate. 2014;74(2):210\u20136.","journal-title":"Prostate"},{"issue":"1","key":"4855_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40644-020-00300-7","volume":"20","author":"BF de Galiza","year":"2020","unstructured":"de Galiza BF, Queiroz MA, Nunes RF, et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;20(1):23.","journal-title":"Cancer Imaging"},{"issue":"12","key":"4855_CR12","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00259-017-3780-7","volume":"44","author":"S Sheikhbahaei","year":"2017","unstructured":"Sheikhbahaei S, Afshar-Oromieh A, Eiber M, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44(12):2117\u201336.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4855_CR13","doi-asserted-by":"publisher","first-page":"684629","DOI":"10.3389\/fonc.2021.684629","volume":"11","author":"R Wang","year":"2021","unstructured":"Wang R, Shen G, Huang M, Tian R. The diagnostic role of 18F-choline, 18F-fluciclovine and 18F-PSMA PET\/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis. Front Oncol. 2021;11:684629.","journal-title":"Front Oncol"},{"key":"4855_CR14","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40336-024-00631-6","volume":"12","author":"S Woo","year":"2024","unstructured":"Woo S, Freedman D, Becker AS, et al. Equivocal bone lesions on PSMA PET\/CT: systematic review and meta-analysis on their prevalence and malignancy rate. Clin Transl Imaging. 2024;12:485\u2013500.","journal-title":"Clin Transl Imaging"},{"issue":"11","key":"4855_CR15","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1007\/s00259-022-05745-5","volume":"49","author":"B Vollnberg","year":"2022","unstructured":"Vollnberg B, Alberts I, Genitsch V, Rominger A, Afshar-Oromieh A. Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET\/CT for prostate cancer-a single-centre experience of PET-guided biopsies. Eur J Nucl Med Mol Imaging. 2022;49(11):3910\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"4855_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1148\/radiol.220218","volume":"305","author":"GA Ulaner","year":"2022","unstructured":"Ulaner GA, Thomsen B, Bassett J, et al. 18F-DCFPyL PET\/CT for initially diagnosed and biochemically recurrent prostate cancer: prospective trial with pathologic confirmation. Radiology. 2022;305(2):419\u201328.","journal-title":"Radiology"},{"issue":"3","key":"4855_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837\u201345.","journal-title":"Biometrics"},{"issue":"2","key":"4855_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2214\/AJR.10.4923","volume":"195","author":"MC Adams","year":"2010","unstructured":"Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195(2):310\u201320.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"4855_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"JH O","year":"2016","unstructured":"O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576\u201384.","journal-title":"Radiology"},{"issue":"1","key":"4855_CR20","first-page":"1","volume":"13","author":"ZJ Wilson","year":"2023","unstructured":"Wilson ZJ, Xu G, Tewari SO, Lu Y. Comparison of PSMA-based 18F-DCFPyL PET\/CT and Tc-99m MDP bone scan in detection of bone metastasis in prostate cancer. Am J Nucl Med Mol Imaging. 2023;13(1):1\u201310.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"4855_CR21","doi-asserted-by":"publisher","unstructured":"Schuster DM, Jani AB, Marcus CV, Chau A, Davis P. PPV of bone uptake of 18F-flotufolastat: evaluation using SPOTLIGHT study data. AJR Am J Roentgenol. 2024;13:1\u20133. (Online ahead of print). https:\/\/doi.org\/10.2214\/AJR.24.31698","DOI":"10.2214\/AJR.24.31698"},{"issue":"8","key":"4855_CR22","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jvir.2017.04.019","volume":"28","author":"MG Holmes","year":"2017","unstructured":"Holmes MG, Foss E, Joseph G, et al. CT-guided bone biopsies in metastatic castration-resistant prostate cancer: factors predictive of maximum tumor yield. J Vasc Interv Radiol. 2017;28(8):1073-1081.e1.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"4855_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/pcan.2014.28","volume":"17","author":"RR McKay","year":"2014","unstructured":"McKay RR, Zukotynski KA, Werner L, et al. Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17(4):325\u201331.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"4855_CR24","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1148\/radiol.13121782","volume":"269","author":"CE Spritzer","year":"2013","unstructured":"Spritzer CE, Afonso PD, Vinson EN, et al. Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer\u2013factors affecting diagnostic success. Radiology. 2013;269(3):816\u201323.","journal-title":"Radiology"},{"issue":"5","key":"4855_CR25","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/cncr.31173","volume":"124","author":"V Sailer","year":"2018","unstructured":"Sailer V, Schiffman MH, Kossai M, et al. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 2018;124(5):1008\u201315.","journal-title":"Cancer"},{"issue":"11","key":"4855_CR26","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.2967\/jnumed.119.241109","volume":"61","author":"AC de Jong","year":"2020","unstructured":"de Jong AC, Smits M, van Riet J, et al. 68Ga-PSMA-guided bone biopsies for molecular diagnostics in patients with metastatic prostate cancer. J Nucl Med. 2020;61(11):1607\u201314.","journal-title":"J Nucl Med"},{"issue":"12","key":"4855_CR27","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.3390\/cancers12123756","volume":"12","author":"M Smits","year":"2020","unstructured":"Smits M, Ekici K, Pamidimarri Naga S, et al. Prior PSMA PET-CT imaging and Hounsfield unit impact on tumor yield and success of molecular analyses from bone biopsies in metastatic prostate cancer. Cancers (Basel). 2020;12(12):3756.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4855_CR28","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bju.15152","volume":"126","author":"MY Chen","year":"2020","unstructured":"Chen MY, Franklin A, Yaxley J, et al. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant? BJU Int. 2020;126(3):396\u2013401.","journal-title":"BJU Int"},{"issue":"13","key":"4855_CR29","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","volume":"48","author":"H Gr\u00fcnig","year":"2021","unstructured":"Gr\u00fcnig H, Maurer A, Thali Y, et al. Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2021;48(13):4483\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"4855_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jvir.2018.08.004","volume":"30","author":"FI Baffour","year":"2019","unstructured":"Baffour FI, Moynagh MR, Eiken PW, et al. Effectiveness and safety of percutaneous CT-guided rib biopsy. J Vasc Interv Radiol. 2019;30(1):82\u20136.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"4855_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13550-016-0177-8","volume":"6","author":"A Sher","year":"2016","unstructured":"Sher A, Lacoeuille F, Fosse P, et al. For avid glucose tumors, the SUV peak is the most reliable parameter for [18F]FDG-PET\/CT quantification, regardless of acquisition time. EJNMMI Res. 2016;6(1):21.","journal-title":"EJNMMI Res"},{"issue":"12","key":"4855_CR32","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2967\/jnumed.119.241174","volume":"61","author":"LW Chiu","year":"2020","unstructured":"Chiu LW, Lawhn-Heath C, Behr SC, et al. Factors predicting metastatic disease in 68Ga-PSMA-11 PET-positive osseous lesions in prostate cancer. J Nucl Med. 2020;61(12):1779\u201385.","journal-title":"J Nucl Med"},{"issue":"3","key":"4855_CR33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2967\/jnumed.122.264334","volume":"64","author":"TE Phelps","year":"2023","unstructured":"Phelps TE, Harmon SA, Mena E, et al. Predicting outcomes of indeterminate bone lesions on 18F-DCFPyL PSMA PET\/CT scans in the setting of high-risk primary or recurrent prostate cancer. J Nucl Med. 2023;64(3):395\u2013401.","journal-title":"J Nucl Med"},{"issue":"12","key":"4855_CR34","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","volume":"51","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D, et al. The homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging. 2024;51(12):3753\u201364.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Skeletal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-024-04855-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00256-024-04855-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-024-04855-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:41:05Z","timestamp":1747269665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00256-024-04855-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["4855"],"URL":"https:\/\/doi.org\/10.1007\/s00256-024-04855-5","relation":{},"ISSN":["0364-2348","1432-2161"],"issn-type":[{"value":"0364-2348","type":"print"},{"value":"1432-2161","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Approval from the Institutional Review Board was obtained and, in keeping with the policies for a retrospective review of existing data, informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"W.C.O, B.E.N, G.M.D, W.L.W, and R.I have no conflicts of interest.J.W.J serves as a consultant and medical advisory board for Boston Scientific, Varian, Stryker, and BD\/Bard, outside the submitted work.T.L.VV serves as a consultant to BD, outside the submitted work.B.A.S reports receiving personal fees from Avid Radiopharmaceuticals, Curium Pharma, Progenics Pharmaceuticals, Lantheus Medical Imaging, Siemens Healthineers (for spouse), Capella Imaging, and GE Healthcare, outside the submitted work; and clinical trial funding from Curium Pharma, Progenics Pharmaceuticals, ImaginAb, and Blue Earth Diagnostics outside the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}